Allergy Desensitization Is an Example of Allergen Immunotherapy
Allergy desensitization is an example of allergen-specific immunotherapy — specifically, active immunotherapy that induces immune tolerance to a defined allergen. It is classified as active (the patient's immune system is trained, not bypassed), specific (targets one or more defined allergens), and tolerance-inducing — distinguishing it from passive immunotherapy (monoclonal antibodies like Xolair) and from pharmacotherapy (antihistamines, intranasal steroids), which suppress symptoms without retraining immunity.
6 peer-reviewed sources
Allergy desensitization is an example of active, allergen-specific immunotherapy — a tolerance-inducing treatment that retrains the immune system to accept a specific allergen. SCIT (allergy shots) can now be self-administered at home by eligible patients through programs like Curex, which supervises dosing via Zoom and requires a prescribed epinephrine auto-injector on hand.
The essentials
Allergy desensitization is an example of allergen immunotherapy — specifically, active, allergen-specific, tolerance-inducing immunotherapy. This is the direct one-sentence answer required by exam questions, board prep materials, and nursing-school coursework. The longer explanation follows the taxonomy.
In immunology, immunotherapy is divided into active and passive categories. Active immunotherapy engages the patient's own immune system to produce the therapeutic effect; passive immunotherapy delivers pre-formed immune effectors (antibodies, lymphocytes) that bypass endogenous immune training. Allergy desensitization falls firmly in the active category: the patient's own T cells and B cells are retrained to produce allergen-specific regulatory responses rather than inflammatory IgE-driven reactions.
Within active immunotherapy, allergy desensitization is allergen-specific — it targets a defined antigen (e.g., grass pollen, house dust mite, cat dander) rather than broadly modulating the immune system. This distinguishes it from general immune-suppressing treatments such as systemic corticosteroids.
The mechanism of tolerance induction (per Cox 2011 Practice Parameter, DOI 10.1016/j.jaci.2010.09.034) involves: induction of allergen-specific regulatory T cells (Tregs), downregulation of Th2 cytokine responses (IL-4, IL-5, IL-13), and IgE-to-IgG4 class-switching in B cells, producing blocking antibodies that compete with IgE for allergen binding.
Distinction from passive immunotherapy: Xolair (omalizumab) is a monoclonal antibody against IgE — it is passive immunotherapy (the therapeutic antibody is externally produced and delivered by injection), not allergen-specific, and does not induce tolerance. When Xolair treatment stops, IgE levels return to baseline and disease recurs.
Distinction from pharmacotherapy: antihistamines (cetirizine, loratadine), intranasal corticosteroids (mometasone, fluticasone), and leukotriene receptor antagonists (montelukast) block downstream mediators of the allergic reaction but do not retrain the immune system. Pharmacotherapy is not immunotherapy.
Patients deciding whether allergen immunotherapy is appropriate can start with Curex's at-home IgE blood test and allergist review, which confirms which allergens are sensitizing and whether at-home SCIT shots or SLIT is clinically indicated for their sensitization profile.
How allergy shots retrain your immune system
The mechanism of allergy desensitization places it definitively in the active immunotherapy category. It requires the patient's own immune cells to respond to the allergen and shift their functional program — no externally produced effectors are delivered.
Allergen-Specific T-Cell Tolerance Induction
Escalating allergen doses expand FOXP3+ CD25+ regulatory T cells (Tregs) and IL-10-producing Tr1 cells. These patient-derived cells produce anti-inflammatory cytokines (IL-10, TGF-beta) that suppress Th2 inflammatory responses to the target allergen. This is active — the patient's T cells are doing the work.
IgE-to-IgG4 Class-Switching (Allergen-Specific)
B cells class-switch from IgE (pathological) to IgG4 (blocking) production, driven by Treg-derived IL-10 and TGF-beta. The IgG4 antibodies produced are allergen-specific — they compete with IgE at the allergen-binding site, preventing mast cell degranulation. This class-switching is achieved by the patient's own B cells, confirming the active mechanism.
Disease-Modifying Durability
Long-lived plasma cells in bone marrow niches continue producing allergen-specific IgG4 after treatment ends. This explains the years-long remission documented in Durham SR et al. (N Engl J Med 1999;341:468-475) — a disease-modifying outcome unique to active immunotherapy, not achievable by passive approaches or pharmacotherapy.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
Allergy desensitization is an example of which type of immunotherapy?
Allergy desensitization is an example of active, allergen-specific immunotherapy — it uses escalating doses of a defined allergen extract to train the patient's own immune system to develop tolerance. Per the AAAAI/ACAAI Practice Parameter Third Update (Cox L, Nelson H, Lockey R et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1-S55, DOI 10.1016/j.jaci.2010.09.034), it is classified as subcutaneous immunotherapy (SCIT) when injected or sublingual immunotherapy (SLIT) when delivered under the tongue. Key classification words: active (patient's immune cells do the work), specific (targets a defined allergen), and tolerance-inducing (retrains rather than suppresses).
How is allergy desensitization different from passive immunotherapy?
Active immunotherapy (allergy desensitization/SCIT) trains the patient's own immune system to produce allergen-specific tolerance — the patient's T cells and B cells undergo permanent functional reprogramming. Passive immunotherapy delivers pre-formed antibodies or immune effectors from an external source: for example, Xolair (omalizumab) is a monoclonal antibody against IgE that blocks IgE from binding to mast cells. Xolair is passive — it does not retrain the patient's immune system, and IgE returns when treatment stops. Allergy desensitization is active — its disease-modifying benefit persists after treatment ends (Durham SR et al., N Engl J Med 1999;341:468-475).
Is allergy desensitization the same as immunosuppression?
No. Allergy desensitization (SCIT/SLIT) is allergen-specific immune modulation — it selectively shifts the immune response to one or more defined allergens from Th2 inflammation to regulatory T-cell tolerance. It does not broadly suppress immune function. Patients undergoing SCIT maintain normal immune responses to pathogens, vaccines, and unrelated allergens. This is distinct from immunosuppressants (systemic corticosteroids, methotrexate, cyclosporine) that broadly reduce immune activity across all antigens.
What is the clinical evidence that allergy desensitization works?
The evidence base for allergen desensitization (SCIT) is among the strongest in allergy medicine. Cochrane meta-analysis (Calderón MA et al., 2007, DOI 10.1002/14651858.CD001936.pub2) across 51 RCTs and 2,871 patients found a symptom SMD of -0.73 (95% CI -0.97 to -0.50) and a medication SMD of -0.57. Durham SR et al. (N Engl J Med 1999;341:468-475) demonstrated disease-modifying remission persisting after a 3-4 year grass-pollen course. Jacobsen L et al. (Allergy 2007;62:943-948) found SCIT prevented asthma in allergic children with an adjusted OR of 4.6 (95% CI 1.5-13.7) at 10-year follow-up.
Can allergy desensitization be done at home?
SCIT (subcutaneous injection desensitization) traditionally required in-office administration, with epinephrine available and a post-injection observation period per Cox 2011 Practice Parameter. The safety record of SCIT (one fatality per 23.3 million injection visits, Epstein 2014) reflects this careful clinical supervision model. At-home self-administration by eligible maintenance patients is now achievable through programs like Curex ($129/month): a prescribed epinephrine auto-injector is confirmed on hand before the first injection, the first injection and every dose change are supervised live over Zoom by the prescribing allergist, the serum is sterile-compounded to USP <797> standards, and a board-certified allergist oversees the full course. SLIT (sublingual immunotherapy) — an alternative form of allergen desensitization — can be taken at home as FDA-approved tablets (Grastek, Oralair, Ragwitek, Odactra), though a supervised first dose is required and tablets carry FDA boxed warnings for anaphylaxis.
How long does allergy desensitization take to work?
Meaningful symptom improvement from allergen desensitization (SCIT) typically begins within 3-6 months of reaching the maintenance dose. Full disease-modifying benefit requires completing the entire 3-5 year course. Cochrane data (Calderón 2007, 51 RCTs) and Durham 1999 NEJM both document benefit that accumulates over the course of treatment and persists after discontinuation. In children, the asthma-prevention effect becomes fully apparent only at 10-year follow-up (Jacobsen 2007 PAT study). Patients should not expect complete relief within the first few months of build-up.
Related Articles
Names of Allergy Shots for Adults | Curex Guide
The clinical name is SCIT. Extracts come from Greer, ALK-Abelló, or Stallergenes Greer. FDA-approved branded tablets: Grastek, Oralair, Ragwitek, Odactra.
Read moreAllergy Vaccines: SCIT Shots & FDA SLIT Tablet Brands
Allergy vaccines (WHO 1998) = SCIT injections plus four FDA-approved SLIT tablets. Neither is a one-time shot — both run a 3–5 year course.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Shots for Humans | Curex Complete SCIT Guide
Yes — allergy shots for humans exist. SCIT has Cochrane SMD −0.73, 51 RCTs, and 1 fatality per 23.3M visits. Not Cytopoint. Not Apoquel. Full guide with pet-allergen disambiguation.
Read moreAllergy Desensitization: SCIT Guide & History | Curex
Allergy desensitization is the historical term for SCIT (allergen immunotherapy). Cochrane 51 RCTs: SMD -0.73. Learn the terminology shift from 1911 to today.
Read moreAllergy Medicine Shot: SCIT vs Xolair vs Steroids | Curex
Allergy medicine shots include SCIT (allergen extract, not a drug), Xolair, Dupixent, and depot steroids. Only SCIT modifies disease. AAAAI discourages routine steroid shots.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.